Kenvue Inc. (NYSE:KVUE) Given Average Recommendation of “Hold” by Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have received a consensus rating of “Hold” from the sixteen research firms that are covering the stock, MarketBeat reports. Thirteen analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.5833.

A number of equities research analysts have recently weighed in on the company. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Barclays raised their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Friday, March 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. UBS Group boosted their price objective on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Finally, Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th.

Hedge Funds Weigh In On Kenvue

A number of hedge funds have recently modified their holdings of KVUE. AlphaCore Capital LLC boosted its holdings in shares of Kenvue by 9.9% during the second quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock worth $111,000 after purchasing an additional 476 shares during the period. Empirical Finance LLC increased its holdings in Kenvue by 1.8% during the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after purchasing an additional 491 shares during the period. J.W. Cole Advisors Inc. raised its position in Kenvue by 3.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock valued at $324,000 after purchasing an additional 574 shares during the last quarter. Physician Wealth Advisors Inc. lifted its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Finally, Mill Creek Capital Advisors LLC lifted its holdings in Kenvue by 0.6% in the 4th quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after buying an additional 701 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $17.45 on Friday. The firm has a market cap of $33.45 billion, a P/E ratio of 22.66, a P/E/G ratio of 3.98 and a beta of 0.51. The firm’s fifty day moving average is $17.96 and its 200 day moving average is $17.24. Kenvue has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the previous year, the firm posted $0.26 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Research analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio is presently 107.79%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.